Navigation Links
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Date:6/17/2008

trated that when used as a first-line consolidation therapy for patients with follicular lymphoma, Zevalin significantly improved the median progression-free survival time from 13.5 months (control arm) to 37 months (p<0.0001).

The primary investigators of the study concluded that Zevalin consolidation of first remission in advanced stage follicular lymphoma is highly effective, resulting in a total complete response (CR + CRu) rate of 87 percent and prolongation of median progression-free survival (PFS) by approximately two years, with a toxicity profile comparable to that seen with Zevalin's use in approved indications. Zevalin-treated patients had reversible Grade 3 or 4 hematologic side effects including neutropenia in 67 percent, thrombocytopenia in 61 percent, and anemia in 3 percent. Nonhematologic toxicities were 23.5% Grade 3, and Grade 3/4 infection was 7.9%.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. Zevalin is also indicated, under accelerated approval, for the treatment of relapsed or refractory, rituximab-naive, low-grade and follicular NHL based on studies using a surrogate endpoint of overall response rate nonhematologic toxicities were 23.5% Grade 3, and Grade 3/4 infection was 7.9%. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab (Rituxan(R)) infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regi
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
2. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
3. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
4. Chromos enters into loan and lending arrangements
5. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
6. CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order
7. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services
8. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
9. Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers
10. Finesse Solutions Expands by Opening Sales and Service Centers
11. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015  Blueprint Medicines (NASDAQ: BPMC ... kinase drugs for genomically defined diseases, today announced that ... a company overview at the 2015 Wedbush PacGrow Healthcare ... EDT. A live webcast of the event ... the Blueprint Medicines website at www.blueprintmedicines.com . An ...
(Date:8/4/2015)... Francisco, CA (PRWEB) , ... August 04, 2015 , ... ... difference by inviting a diverse selection of entrepreneurs from across the United States to ... CEO Jessica Richman is honored to be chosen to be among the attendees. , ...
(Date:8/4/2015)... , Aug. 4, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: ... in China , today announced that ... second quarter, ended June 30, 2015, after market close ... conference call on Thursday, August 13, 2015, at 8:00 ... China Standard Time) to review the Company,s financial results ...
(Date:8/3/2015)... GREENVILLE, N.C. , Aug. 3, 2015 /PRNewswire/ ... will unveil its new Fingerprint Molecular Identification™ (FMID) ... Identification,s educational conference in Sacramento, Calif. ... in forensic science, will enable law enforcement agents, ... molecular profile of criminal suspects. By ...
Breaking Biology Technology:White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results 2ArroGen Previews New Fingerprint Molecular Identification Technology 2
... NEW YORK, April 28, 2011 Keryx Biopharmaceuticals (Nasdaq: ... from the Phase 3 short-term clinical trial of Zerenex ... in end-stage renal disease patients on dialysis.  The Zerenex ... Foundation Spring Clinical Meetings being held in Las Vegas, ...
... Mich., April 28, 2011 Vestaron Corporation, a Kalamazoo-based ... products, announced today that John Sorenson, Ph.D., will serve ... of Directors thanks John McIntyre for his years of ... agriculture. "John,s scientific leadership has been just ...
... Genomatica , an emerging leader in ... chemical maker in the world, signed a broad memorandum of ... , Study of a j oint venture ... Asia :  Mitsubishi and Genomatica will explore forming a joint ...
Cached Biology Technology:Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study 2Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study 3Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study 4Vestaron Corporation Announces New Leadership 2Vestaron Corporation Announces New Leadership 3Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia 2Mitsubishi Chemical Corporation Signs Memorandum of Understanding for Strategic Partnership With Genomatica for Sustainable Chemicals in Asia 3
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
(Date:7/31/2015)... , July 31, 2015 The 10 th ... be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th anniversary this ... of the world,s most influential annual meetings in the ,omics, ... enjoyable scientific gatherings. ICG-10 focuses on recent ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... near stagnation, four new drugs could help make advanced prostate ... leading Colorado prostate cancer expert says. "It,s not just ... One is a bone protective agent; another,s a more effective ... the first drug tested for cancer immunotherapy," says E. David ...
... New York (February 16, 2012)The Republic of Congo ... increasingly rare treasure: one of Africa,s most pristine forests ... exposure to humans that the curious apes investigate the ... Known as the Goualougo Triangle, the 100-plus square-mile dense ...
... have found a way to generate and maintain stem cells ... protein., Researchers from Denmark, Scotland and the USA have created ... such as skin cells so that they can subsequently ... cells have the potential to become any cell in the ...
Cached Biology News:4 new drugs will change prostate cancer care 2Great news for chimpanzees 2Great news for chimpanzees 3Synthetic protein amplifies genes needed for stem cells 2Synthetic protein amplifies genes needed for stem cells 3
... to rapidly and reliably amplify unknown ... APA Technology. APAgene provides hassle-free, ready-to ... price. All necessary ingredients are provided ... can be used for identifying transgene/genomic ...
Recommended for supporting the growth of anchorage-dependent cells including human and mouse stromal cells, mesenchymal cells and cell lines....
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: cap, ...
Extremely high efficiency packaging extracts useful for transfecting our EpiFOS™ or CopyControl™ Fosmids, or any DNA vector with cos sites. A tremendous value when conpared to the competition...
Biology Products: